BlossomHill Therapeutics Inc. (BLSM) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, BlossomHill Therapeutics Inc. (NASDAQ: BLSM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $13.75 (-9.60% 1D, market cap $483.4M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BLSM carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MNPR (Monopar Therapeutics Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -17.4%, cap $482.7M) and FTH (Faeth Therapeutics Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $484.5M). Among the 5-stock peer group, BLSM leads on earnings multiple (N/A) while MNPR leads on capital efficiency (-17.4% ROIC).
Per BLSM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001839970), BlossomHill Therapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $163.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL FY 2025 (10-K): 0.3% FCF Margin ($13.5M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While BLSM currently carries a cautious 42/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($18.95) and Max Pain ($14.44) forces dealer call-delta covering toward $29.39.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
BlossomHill Therapeutics Inc. (BLSM) dropped -9.60% to $13.75, trading at 5% of its 52-week range ($12.93 – $27.99). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Seeking Alpha report covering BlossomHill Therapeutics Inc. (BLSM) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering BlossomHill Therapeutics Inc. (BLSM) market action, institutional positioning, and fundamental catalysts.
TradingView report covering BlossomHill Therapeutics Inc. (BLSM) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering BlossomHill Therapeutics Inc. (BLSM) market action, institutional positioning, and fundamental catalysts.
GlobeNewswire report covering BlossomHill Therapeutics Inc. (BLSM) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering BlossomHill Therapeutics Inc. (BLSM) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering BlossomHill Therapeutics Inc. (BLSM) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering BlossomHill Therapeutics Inc. (BLSM) market action, institutional positioning, and fundamental catalysts.
BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BLSM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BLSM. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, BlossomHill Therapeutics Inc. (BLSM) ranks #472 by composite RQD confidence (42/100, grade D-) and #459 by equity capitalization ($483.4M). Within this direct 5-issuer industry benchmark cohort, BLSM leads on earnings valuation at N/A trailing P/E, while MNPR leads on capital efficiency and profitability with -17.4% ROIC and — gross margin. BLSM currently leads its immediate peer cohort in composite quantitative strength at 42/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BLSM
ACTIVE
BlossomHill Therapeutics Inc. | D- | 42/100 | — | — | — | -9.60% | $483.4M | Benchmark Subject |
| MNPR Monopar Therapeutics Inc. | E | 27/100 | — | — | -17.4% | -2.21% | $482.7M | /mnpr-vs-blsm → |
| FTH Faeth Therapeutics Inc. | E | 29/100 | — | — | -35.0% | -0.32% | $484.5M | /fth-vs-blsm → |
| EOLS Evolus Inc. | E | 27/100 | — | 66.3% | -35.0% | -2.26% | $496.7M | /eols-vs-blsm → |
| CTMX CytomX Therapeutics Inc. | E | 14/100 | — | — | -20.5% | +2.18% | $499.0M | /ctmx-vs-blsm → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), BlossomHill Therapeutics Inc. (BLSM) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, BLSM closed FY2025 with $163.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $0 | — | — | $163.0M | — |
As of 2026-11-02, BlossomHill Therapeutics Inc. (NASDAQ: BLSM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $13.75 (-9.60% 1D, market cap $483.4M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BLSM carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MNPR (Monopar Therapeutics Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -17.4%, cap $482.7M) and FTH (Faeth Therapeutics Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $484.5M). Among the 5-stock peer group, BLSM leads on earnings multiple (N/A) while MNPR leads on capital efficiency (-17.4% ROIC).
Per BLSM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001839970), BlossomHill Therapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $163.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
BLSM last traded at $13.75 (-9.60% on volume of 156,302 shares), positioning the stock -27.44% below its 50-day simple moving average ($18.95) and -25.51% below its 200-day simple moving average ($18.46). Across its 52-week range of $12.93 to $27.99, BLSM sits at the 5.4% percentile with a 14-day RSI of 44.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($12.03 to $15.47).
Why BLSM Stock dropped -9.60% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, BLSM scores 42 out of 100, a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars:
For a prospective investor evaluating the stock today, the practical takeaway is that the rating is driven by the absence of earnings, cash return, and supportive institutional or insider flow, partly offset by a balance sheet that is not flagged as distressed. Valuation cannot be assessed from the source data because P/E and EV/EBITDA are unavailable, so the rating should be read as a statement about current fundamentals and flow rather than a price-target judgment.
BlossomHill Therapeutics Inc. (BLSM) is a NASDAQ-listed company in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations, per the company profile. The profile does not describe its specific products, customers, or revenue model. Per the SEC financials, reported revenue for FY 2025 is $0.0M, so the source data does not show a revenue-generating operation in the period covered. Not available in source data: product portfolio details, customer base, and monetization structure.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 (filed 2025-12-31) | $0.0M | $0.0M | $0.0M | N/A | N/A | $136.7M | N/A |
Per the SEC financials, the company reported no revenue, operating income, or net income for FY 2025, and margins are recorded as 0% across gross, operating, and net. ROIC is 0% per the market data. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 6 out of 9, with a Debt/Equity ratio of 0.5. Reported cash of $136.7M is the main balance-sheet figure in the source data, while debt is recorded as N/A.
Per the recent news wire, the most material item is a GlobeNewswire release announcing a collaboration with Foundation Medicine to develop a first companion diagnostic for BH-30643 in EGFR C797S mutated non-small cell lung cancer. This is the only item in the source data describing a clinical or commercial development. The remaining items are market-action reports from Seeking Alpha, MarketBeat, and TradingView, all flagged "RISK WATCH" with a red signal, covering share price declines and an average target price of $35.00.
Per the Butterfly Supply-Chain Graph, there is one proprietary signal: a LIQUIDITY_TAILWIND of bearish direction with a severity score of 94. Its terminal label is a Macro Tailwind Score of 18 out of 100. The signal reports True Net Liquidity falling -0.64% over four weeks to $5,746B, an elasticity of 6.00x beta, and a 2 bps widening in HY OAS, with a correlation of r=+0.17 and a z-score of 6.1. These are macro-liquidity readings and do not describe company-specific events.
Real-time company headlines, analyst actions, and sector developments for BlossomHill Therapeutics Inc. (BLSM) • Click "Debate This Headline" to argue it in the Roar Pit below
Seeking Alpha report covering BlossomHill Therapeutics Inc. (BLSM) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering BlossomHill Therapeutics Inc. (BLSM) market action, institutional positioning, and fundamental catalysts.
TradingView report covering BlossomHill Therapeutics Inc. (BLSM) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering BlossomHill Therapeutics Inc. (BLSM) market action, institutional positioning, and fundamental catalysts.
GlobeNewswire report covering BlossomHill Therapeutics Inc. (BLSM) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering BlossomHill Therapeutics Inc. (BLSM) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering BlossomHill Therapeutics Inc. (BLSM) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering BlossomHill Therapeutics Inc. (BLSM) market action, institutional positioning, and fundamental catalysts.
Welcome to the BLSM (BlossomHill Therapeutics Inc.) Roar Pit. Current RQD Composite is 42/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on BLSM, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless BlossomHill Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on BLSM, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $15.21 (52-wk range $12.93 - $27.99), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).